H.C. Wainwright raised the firm’s price target on Longboard Pharmaceuticals to $80 from $60 and keeps a Buy rating on the shares. The firm believes end-of-Phase 2 discussions with the FDA as well as an improved understanding and awareness of the developmental and epileptic encephalopathies have supported a broader program for the company.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard treatment of Dravet syndrome granted orphan designation
- Longboard Pharmaceuticals initiated with a Buy at Truist
- Longboard announces interim analysis results from OLE Phase 1b/2a PACIFIC study
- Truist healthcare analyst holds an analyst/industry conference call
- Longboard Pharmaceuticals price target raised to $45 from $36 at B. Riley